UiPath (NYSE:PATH) Stock Rating Lowered by Mizuho

UiPath (NYSE:PATHGet Rating) was downgraded by stock analysts at Mizuho from a “buy” rating to a “neutral” rating in a report released on Wednesday, MarketBeat reports. They currently have a $14.00 target price on the healthcare company’s stock, down from their prior target price of $40.00. Mizuho’s target price indicates a potential upside of 0.36% from the company’s previous close.

A number of other research firms have also recently weighed in on PATH. Barclays decreased their price objective on UiPath from $36.00 to $25.00 in a research report on Friday, May 20th. Oppenheimer reduced their price target on UiPath from $35.00 to $23.00 and set a “buy” rating for the company in a report on Thursday, June 2nd. Wells Fargo & Company reduced their price target on UiPath from $35.00 to $30.00 in a report on Wednesday, May 18th. Morgan Stanley cut UiPath from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $32.00 to $15.00 in a report on Wednesday. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $25.00 price target on shares of UiPath in a report on Thursday, July 7th. Seven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.97.

UiPath Stock Up 0.8 %

Shares of NYSE PATH opened at $13.95 on Wednesday. The stock has a market cap of $7.60 billion, a PE ratio of -17.44 and a beta of 0.11. UiPath has a 52-week low of $12.21 and a 52-week high of $59.57. The business has a 50-day moving average price of $18.84 and a 200 day moving average price of $21.08.

UiPath (NYSE:PATHGet Rating) last posted its quarterly earnings data on Tuesday, September 6th. The healthcare company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.09. UiPath had a negative return on equity of 19.07% and a negative net margin of 42.98%. The company had revenue of $242.22 million during the quarter, compared to analysts’ expectations of $230.68 million. During the same period last year, the firm earned ($0.17) EPS. The firm’s revenue for the quarter was up 23.9% on a year-over-year basis. Sell-side analysts anticipate that UiPath will post -0.59 earnings per share for the current year.

Insider Transactions at UiPath

In other news, CFO Ashim Gupta sold 100,000 shares of the firm’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $20.70, for a total transaction of $2,070,000.00. Following the sale, the chief financial officer now owns 1,387,266 shares in the company, valued at $28,716,406.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Ashim Gupta sold 100,000 shares of the firm’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $20.70, for a total transaction of $2,070,000.00. Following the sale, the chief financial officer now owns 1,387,266 shares in the company, valued at $28,716,406.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Hitesh Ramani sold 22,800 shares of the firm’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $20.70, for a total value of $471,960.00. Following the sale, the chief accounting officer now owns 426,799 shares in the company, valued at approximately $8,834,739.30. The disclosure for this sale can be found here. Insiders have sold 125,321 shares of company stock worth $2,589,103 over the last quarter. 31.88% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PATH. Northern Trust Corp boosted its holdings in UiPath by 32.0% in the fourth quarter. Northern Trust Corp now owns 639,274 shares of the healthcare company’s stock valued at $27,572,000 after acquiring an additional 155,090 shares during the last quarter. First Trust Advisors LP boosted its holdings in UiPath by 38.0% in the fourth quarter. First Trust Advisors LP now owns 121,297 shares of the healthcare company’s stock valued at $5,232,000 after acquiring an additional 33,369 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its holdings in UiPath by 73.1% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 39,487 shares of the healthcare company’s stock valued at $1,703,000 after acquiring an additional 16,681 shares during the last quarter. Aviva PLC acquired a new position in UiPath in the fourth quarter valued at $3,429,000. Finally, TD Asset Management Inc. boosted its holdings in UiPath by 74.5% in the fourth quarter. TD Asset Management Inc. now owns 1,163,947 shares of the healthcare company’s stock valued at $50,201,000 after acquiring an additional 496,999 shares during the last quarter. Institutional investors and hedge funds own 51.35% of the company’s stock.

UiPath Company Profile

(Get Rating)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

Read More

Analyst Recommendations for UiPath (NYSE:PATH)

Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.